Immunome, Inc. (IMNM) Intrinsic Value

DCF-based fair value calculation with Bear, Base, and Bull scenarios

Popular:

Immunome, Inc. (IMNM)

View Full Profile →

Intrinsic Value

DCF Not Suitable for IMNM

Revenue ($10M) below $1B threshold — insufficient business scale for DCF.

Alternative Approach:

Use EV/Sales vs. industry peers for growth-stage companies.

Frequently Asked Questions

Is IMNM stock undervalued or overvalued?

Insufficient data to compute DCF valuation for IMNM. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.

What is IMNM's intrinsic value?

Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.

How is IMNM's fair value calculated?

Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For IMNM, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.